Literature DB >> 22950508

Central actions of somatostatin-28 and oligosomatostatin agonists to prevent components of the endocrine, autonomic and visceral responses to stress through interaction with different somatostatin receptor subtypes.

Andreas Stengel1, Jean Rivier, Yvette Taché.   

Abstract

Somatostatin was discovered four decades ago and since then its physiological role has been extensively investigated, first in relation with its inhibitory effect on growth hormone secretion but soon it expanded to extrapituitary actions influencing various stressresponsive systems. Somatostatin is expressed in distinct brain nuclei and binds to five somatostatin receptor subtypes which are also widely expressed in the brain with a distinct distribution pattern. The last few years witnessed the discovery of highly selective peptide somatostatin receptor agonists and antagonists representing valuable tools to delineate the respective pathways of somatostatin signaling. Here we review the centrally mediated actions of somatostatin and related selective somatostatin receptor subtype agonists to influence the endocrine, autonomic, and visceral components of the stress response and basal behavior as well as thermogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22950508      PMCID: PMC3683309          DOI: 10.2174/13816128130114

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  101 in total

Review 1.  Regulation and function of somatostatin receptors.

Authors:  Gisela Olias; Cécile Viollet; Heike Kusserow; Jacques Epelbaum; Wolfgang Meyerhof
Journal:  J Neurochem       Date:  2004-06       Impact factor: 5.372

2.  Central site of action of somatostatin (SRIF): role of hippocampus.

Authors:  M Rezek; V Havlicek; K R Hughes; H Friesen
Journal:  Neuropharmacology       Date:  1976-08       Impact factor: 5.250

3.  N-terminally extended somatostatin: the primary structure of somatostatin-28.

Authors:  L Pradayrol; H Jörnvall; V Mutt; A Ribet
Journal:  FEBS Lett       Date:  1980-01-01       Impact factor: 4.124

4.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

5.  Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro.

Authors:  Mark Connor; Elena E Bagley; Vanessa A Mitchell; Susan L Ingram; MacDonald J Christie; Patrick P A Humphrey; Christopher W Vaughan
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

6.  Suppression of feeding and drinking activity in rats following intraventricular injection of thyrotropin releasing hormone (TRH).

Authors:  E Vijayan; S M McCann
Journal:  Endocrinology       Date:  1977-06       Impact factor: 4.736

7.  Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice.

Authors:  Vicente Martínez; Lixin Wang; Jean Rivier; Dimitri Grigoriadis; Yvette Taché
Journal:  J Physiol       Date:  2004-01-30       Impact factor: 5.182

8.  Somatostatin actions on rat supraoptic nucleus oxytocin and vasopressin neurones.

Authors:  S L Meddle; P M Bull; G Leng; J A Russell; M Ludwig
Journal:  J Neuroendocrinol       Date:  2010-02-23       Impact factor: 3.627

9.  Somatostatin analog: plasma catecholamine suppression mediated by the central nervous system.

Authors:  D A Fisher; M R Brown
Journal:  Endocrinology       Date:  1980-09       Impact factor: 4.736

10.  Neostriatal administration of somatostatin:differential effect of small and large doses on behavior and motor control.

Authors:  M Rezek; V Havlicek; L Leybin; C Pinsky; E A Kroeger; K R Hughes; H Friesen
Journal:  Can J Physiol Pharmacol       Date:  1977-04       Impact factor: 2.273

View more
  6 in total

1.  Depleting hypothalamic somatostatinergic neurons recapitulates diabetic phenotypes in mouse brain, bone marrow, adipose and retina.

Authors:  Chao Huang; Robert F Rosencrans; Raluca Bugescu; Cristiano P Vieira; Ping Hu; Yvonne Adu-Agyeiwaah; Karen L Gamble; Ana Leda F Longhini; Patrick M Fuller; Gina M Leinninger; Maria B Grant
Journal:  Diabetologia       Date:  2021-08-24       Impact factor: 10.122

Review 2.  Illuminating somatostatin analog action at neuroendocrine tumor receptors.

Authors:  Jean Claude Reubi; Agnes Schonbrunn
Journal:  Trends Pharmacol Sci       Date:  2013-10-31       Impact factor: 14.819

3.  Somatostatin, neuronal vulnerability and behavioral emotionality.

Authors:  L C Lin; E Sibille
Journal:  Mol Psychiatry       Date:  2015-01-20       Impact factor: 15.992

Review 4.  The functional state of hormone-sensitive adenylyl cyclase signaling system in diabetes mellitus.

Authors:  Alexander O Shpakov; Kira V Derkach
Journal:  J Signal Transduct       Date:  2013-09-28

5.  Cell Type-Specific Expression of Corticotropin-Releasing Hormone-Binding Protein in GABAergic Interneurons in the Prefrontal Cortex.

Authors:  Kyle D Ketchesin; Nicholas S Huang; Audrey F Seasholtz
Journal:  Front Neuroanat       Date:  2017-10-10       Impact factor: 3.856

6.  Characterization of Neurons Expressing the Novel Analgesic Drug Target Somatostatin Receptor 4 in Mouse and Human Brains.

Authors:  Angéla Kecskés; Krisztina Pohóczky; Miklós Kecskés; Zoltán V Varga; Viktória Kormos; Éva Szőke; Nóra Henn-Mike; Máté Fehér; József Kun; Attila Gyenesei; Éva Renner; Miklós Palkovits; Péter Ferdinandy; István M Ábrahám; Balázs Gaszner; Zsuzsanna Helyes
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.